Perrigo Feels Ill Effects Of Mild Cold Season, Excess OTC Capacity
This article was originally published in The Tan Sheet
Executive Summary
The private labeler lowered its full-year revenue guidance, noting weak cough/cold/flu OTC sales. Perrigo built up excess capacity to take advantage of recalled Johnson & Johnson OTCs, and now is shifting some capacity in response to a Novartis plant shutdown.
You may also be interested in...
Bayer Migraine Formula Seeks Market Share Before Excedrin Returns
Bayer Migraine Formula, already in major retailers nationwide, is “a welcome addition to the pain relief aisle for migraine sufferers … affected by the OTC supply issues this year,” the firm says, referring to Novartis’ voluntarily recall of Excedrin.
Bayer Migraine Formula Seeks Market Share Before Excedrin Returns
Bayer Migraine Formula, already in major retailers nationwide, is “a welcome addition to the pain relief aisle for migraine sufferers … affected by the OTC supply issues this year,” the firm says, referring to Novartis’ voluntarily recall of Excedrin.
OTC Answers Website Plays Up Brands In Self-Selection Engine
Drug companies will have the opportunity to sponsor content categories and place products in the MyOTC recommendation engine on OTCAnswers.com. CEO Donald Blust wants the website to help boost branded products as they push back against private label.